Krish Patel, MD

Providing access to highly effective therapies in the communities where patients live is critical to improving outcomes. Safety of bsabs and CAR-T is continuously improving and we need partnerships to bring these therapies to more community oncology centers. #HemOnc #lymsm #MedSky

SCRI expert, Dr. Stephen Strickland presented interim results for SENTI-202 at #AACR2025. This CAR NK cell therapy shows potential in treating relapsed AML, with several patients achieving complete remission. Read more www.usnews.com/news/health-...
#CancerResearch #CAR_NK_Therapy #AML #USNews

This is so incredibly sad for cancer and specifically cell and gene therapy. I am profoundly grateful to Peter for his service, collaboration and dedication through an incredibly impactful career. CAR-T therapies would not be where they are without his efforts. www.wsj.com/politics/top...

RFK Jr. forces out Peter Marks, FDA’s top vaccine scientist Marks, an architect of Operation Warp Speed for coronavirus vaccines, warned that a measles outbreak shows how confidence in science is being “undermined.”

We owe him much for his leadership at CBER during a period of remarkable therapeutic advances. The havoc caused by this administration will have a devastating impact for years.

www.washingtonpost.com/politics/202...

So many exciting developments in MCL in the past few years. Much more to come also with a lot of exciting clinical trials and investigational therapies being developed. #lymsm #HemeSky

Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial FT596 was well tolerated as monotherapy or with rituximab and induced deep and durable responses in patients with indolent and aggressive lymphomas and the RP2D was preliminarily identified to be 1·8 × 109 cells for three doses per cycle. This study supports that cell therapy using iPSC-derived, gene-modified NK cells is a potent platform for cancer treatment and suggests that such a platform might address limitations of currently available immune cell therapies, including manufacturing time, heterogeneity, access, and cost.

Long awaited…Excited to see our multi-center effort of CD19 allo iPSC CAR-NK in B-cell #lymsm! Impt proof of concept:
-very low CRS ✅
-no ICANS ✅
-multi dose off shelf tx ✅
-durable responses in challenging histologies ✅
Lots still to do for the field of CAR-NK www.thelancet.com/journals/lan...

Amazing and very important work for the field. 👏🏽👏🏽👏🏽

@majorajay.bsky.social was on 🔥🔥🔥while being a super dad 👏🏽👏🏽🙌🏽

Every year this is how I feel after ASH. A final #ASHaiku

Every year it comes
ASH conference lights the path
Purpose renewed

#ASH24 #hematology #HemeSky #lymsm

Having worked on several investigational cd3-cd20 bsAbs I have (across programs) a number of r/r LBCL pts >4-5yrs out from monotherapy without relapse and never consolidated. Hard to imagine those patients havent been cured…the ? In my ming though is what % are at current approved doses/indications…

Excited to be at ASH in my new role at SCRI! Stop by our booth to learn about exciting things happening in our network! #ASH24 #lymsm #CancerResearch

Targeting BTK to treat CLL and NHL: insights from BTKis and novel BTK degraders | VJHemOnc In this video, Tanya Siddiqi, MD, City of Hope, Duarte, CA, Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, and...

Want to hear about the targeting of BTK for the treatment of CLL and NHL?

Then don't forget to watch our fantastic roundtable discussion with experts Tanya Siddiqi, Krish Patel & Alexey Danilov!

Click here:
👉https://buff.ly/4f3mR7s👈

#iwNHL24 #LYMsm #CLLsm #NonHodgkinLymphoma

On the way to @ash-hematology.bsky.social 2024. Beautiful middle TN sunrise over Cumberland River. Excited for science, collaboration, and all the best of #hematology #hemesky #lymsm #lymsky #ASH2024

A very exciting time to join Sarah Cannon. Cutting edge research in rapidly growing programs.

Looking forward to full study presentation. I like the approach but devil is in the details. Followup is short and mPFS 16 mths R2 control arm not quite performing like AUGMENT (where R2 median pfs 27.6mths at 5yr f/u) but it is a randomized comparison. Are pts higher risk in this study 🤔?
#lymsm

Glofi-PolaRCHP 95/97% pfs/os 👀🤯